Literature DB >> 28098400

Role of Contrast-Enhanced Sonography in the Evaluation of Axillary Lymph Nodes in Breast Carcinoma: A Monocentric Study.

Giacomo Agliata1, Gianluca Valeri2, Giulio Argalia2, Elisa Tarabelli3, Gian Marco Giuseppetti2.   

Abstract

OBJECTIVES: To evaluate the diagnostic performance of contrast-enhanced sonography for characterization of the lymph node status (metastatic or not) in patients with breast carcinomas by comparison with sentinel lymph node biopsy.
METHODS: From January to August 2015, 50 female patients with a histologic diagnosis of invasive breast carcinoma were prospectively examined by ipsilateral axillary contrast-enhanced sonography. The test was performed by a single radiologist using an ultrasound system with a broadband 8-12-MHz, 38-mm high-resolution linear transducer. For the target lymph node, we chose a node with a sonographic pattern that was suspicious for malignancy: ie, a longitudinal-to-transverse diameter ratio of less than 2, absence of a central hyperechogenic hilum, or both. In cases with a lack of sonographic signs of malignancy, we evaluated the node with the maximal transverse diameter. Nodes were considered malignant in cases with total absence of contrast enhancement and in those with enhancement alterations. Within 1 week, all patients underwent sentinel lymph node biopsy, followed by a histologic test.
RESULTS: The histologic test showed benignity in 22 of 50 sentinel lymph nodes, whereas 28 were metastatic. Among the 22 patients with negative biopsy results, contrast-enhanced sonography showed 18 concordances and 4 false-positives results; among the 28 with positive biopsy results, contrast-enhanced sonography obtained 100% correct characterizations of the axillary status. The sensitivity, specificity, and accuracy were 100%, 82%, and 92%, respectively.
CONCLUSIONS: Contrast-enhanced sonography appears to be a method with high accuracy for characterization of axillary lymph nodes, very close to the reference-standard sentinel lymph node biopsy. This technique seems to have overall high sensitivity.
© 2017 by the American Institute of Ultrasound in Medicine.

Entities:  

Keywords:  breast neoplasm; breast ultrasound; contrast-enhanced sonography; lymph node metastasis

Mesh:

Substances:

Year:  2017        PMID: 28098400     DOI: 10.7863/ultra.16.04012

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  6 in total

1.  Preoperative localization of sentinel lymph nodes using percutaneous contrast-enhanced ultrasonography in patients with breast cancer.

Authors:  Yi-Lin Xu; Xue-Jing Liu; Ying Zhu; Hong Lu
Journal:  Gland Surg       Date:  2022-02

2.  An optimised search strategy is necessary to ensure a thorough search of the literature.

Authors:  Jiangfeng Wu; Peipei Yu; Jingwen Zhang; Qingqing Fang
Journal:  Quant Imaging Med Surg       Date:  2022-04

3.  Sentinel Lymph Node Characterization with a Dual-Targeted Molecular Ultrasound Contrast Agent.

Authors:  Kibo Nam; Maria Stanczak; Flemming Forsberg; Ji-Bin Liu; John R Eisenbrey; Charalambos C Solomides; Andrej Lyshchik
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

Review 4.  Contrast-Enhanced Ultrasonography in the Diagnosis and Treatment Modulation of Breast Cancer.

Authors:  Ioana Boca Bene; Sorin M Dudea; Anca I Ciurea
Journal:  J Pers Med       Date:  2021-01-30

5.  Application of conventional ultrasonography combined with contrast-enhanced ultrasonography in the axillary lymph nodes and evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.

Authors:  Xue Han; Shiyang Jin; Huajing Yang; Jinxing Zhang; Zhenfeng Huang; Jiguang Han; Chuan He; Hongyan Guo; Yue Yang; Ming Shan; Guoqiang Zhang
Journal:  Br J Radiol       Date:  2021-09-01       Impact factor: 3.629

6.  Diagnostic efficacy of sentinel lymph node in breast cancer under percutaneous contrast-enhanced ultrasound: An updated meta-analysis.

Authors:  Huadong Deng; Jianming Lei; Lixian Jin; Hongwei Shi
Journal:  Thorac Cancer       Date:  2021-10-04       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.